Skip to main content

Lymphoma

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

FDA Approvals, Lymphoma, Select Drug Profiles

FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma

FDA Approvals, Lymphoma, Select Drug Profiles

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

Chase Doyle

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

Chase Doyle

FDA Approvals, Lymphoma

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

Leukemia, Lymphoma

Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Chase Doyle

Leukemia, Lymphoma

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma

Wayne Kuznar

Leukemia, Lymphoma

CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma

Chase Doyle

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Chase Doyle

1
2
3

Page 1 of 3
Results 1 - 10 of 29